Status:
COMPLETED
Treating Primary Progressive Aphasia (PPA) Using High-definition tDCS
Lead Sponsor:
University of Pennsylvania
Conditions:
Primary Progressive Aphasia
Eligibility:
All Genders
45-80 years
Phase:
PHASE2
Brief Summary
This is a double-blind, sham-controlled, crossover study in which subjects with the non-fluent/agrammatic and logopenic variants of primary progressive aphasia (naPPA and lvPPA, respectively) will und...
Detailed Description
The central framework for the project is a double-blind, sham-controlled, crossover study in which subjects with the non-fluent/agrammatic and logopenic variants of primary progressive aphasia (naPPA ...
Eligibility Criteria
Inclusion
- Presence of aphasia attributable to nonfluent agrammatic PPA (naPPA) or logopenic variant PPA (lvPPA)
- High school education (or more)
- Must be able to understand the nature of the study, and give informed consent
- Native English speaker
Exclusion
- Presence of additional neurological illness such as stroke or traumatic brain injury
- Diagnosis of epilepsy or reoccurening seizures
- Pacemaker or ICDs
- Craniotomy or skull breech
- Small vessel disease
Key Trial Info
Start Date :
August 17 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2025
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT04046991
Start Date
August 17 2020
End Date
June 30 2025
Last Update
October 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104